NetworkNewsBreaks – ARCA Biopharma, Inc. (NASDAQ: ABIO) Launches New Development Program to Evaluate AB201 for Treatment of COVID-19 Associated CAC
ARCA biopharma (NASDAQ: ABIO) today announced a new development program to evaluate AB201 (“rNAPc2”), a potent, selective inhibitor of tissue factor (“TF”), as a potential treatment for COVID-19 associated coagulopathy (“CAC”) and the related inflammatory response. According to the update, CAC is one of the most serious adverse effects seen in COVID-19 patients. “During this global health crisis, we believe it is important to rapidly and collaboratively evaluate multiple technologies to address COVID-19 and the associated pathologic host responses,” Dr. Michael Bristow, ARCA’s president and CEO, who is also an American Heart Association (“AHA”) funded COVID-19 investigator, stated in the…







